|
1
|
Tsimberidou AM, O’Brien S, Kantarjian HM,
Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE and
Keating MJ: Hodgkin transformation of chronic lymphocytic leukemia:
the MD Anderson Cancer Center experience. Cancer. 107:1294–1302.
2006. View Article : Google Scholar
|
|
2
|
Almhanna K, Wongchawart N and Sweetenham
J: Intracerebral Hodgkin’s lymphoma in a patient with chronic
lymphocytic leukemia/small lymphocytic lymphoma: a case report and
literature review. Cancer Invest. 27:215–220. 2009.
|
|
3
|
Prochorec-Sobieszek M, Majewski M,
Sikorska A, Kos K, Huszcza S and Maryniak RK: Localized gastric
diffuse large B-cell lymphoma and Hodgkin’s lymphoma as secondary
neoplasms in two patients with chronic lymphocytic leukemia. Leuk
Lymph. 47:2244–2246. 2006.
|
|
4
|
Roddie C, Cwynarski K, Craig C, Diss T and
McNamara C: Hodgkin transformation of newly diagnosed small
lymphocytic lymphoma in the gastrointestinal tract. Leuk Lymph.
48:1644–1646. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adiga GU, Abebe L and Wiernik PH:
Partially successful treatment of a patient with chronic
lymphocytic leukemia and Hodgkin’s disease: case report and
literature review. Am J Hematol. 72:267–273. 2003.PubMed/NCBI
|
|
6
|
Robertson LE, Pugh W, O’Brien S,
Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F
and Keating MJ: Richter’s syndrome: a report on 39 patients. J Clin
Oncol. 11:1985–1989. 1993.
|
|
7
|
Brecher M and Banks PM: Hodgkin’s disease
variant of Richter’s syndrome. Report of eight cases. Am J Clin
Pathol. 93:333–339. 1990.
|
|
8
|
Kanzler H, Kuppers R, Helmes S, Wacker HH,
Chott A, Hansmann ML and Rajewsky K: Hodgkin and
Reed-Sternberg-like cells in B-CLL chronic lymphocytic leukemia
represent the outgrowth of single germinal-center B-cell-derived
clones: potential precursors of Hodgkin and Reed-Sternberg cells in
Hodgkin’s disease. Blood. 95:1023–1031. 2000.PubMed/NCBI
|
|
9
|
Fong D, Kaiser A, Spizzo G, Gastl G and
Tzankov A: A Hodgkin’s disease variant of Richter’s syndrome in
chronic lymphocytic leukemia patients previously treated with
fludarabine. Br J Haematol. 129:199–205. 2005.
|
|
10
|
Dujardin F, Lefrancq T, Bléchet C,
Boni-Boka M, Sénecal D, Desmoulins I and Guyetant S: Syndrome de
Richter de type pseudohodgkinien. A propos de deux cas et revue de
la literature. Annales de Pathologie. 28:311–316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lazzarino M, Orlandi E, Baldanti F,
Furione M, Pagnucco G, Astori C, Arcaini L, Viglio A, Paulli M,
Gerna G and Bernasconi C: The immunosuppression and potential for
EBV reactivation of fludarabine combined with cyclophosphamide and
dexamethasone in patients with lymphoproliferative disorders. Br J
Haematol. 107:877–882. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niscola P, Principe MI, Palombi M, et al:
Hodgkin lymphoma in a mutated ZAP-70-negative B-cell chronic
lymphocytic leukemia patient. Leuk Res. 32:362–365. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cerny J, Wang S, Miron P, Hutchinson L and
Brettler D: EBV-negative Hodgkin lymphoma in ZAP-70-positive B-cell
lymphocytic leukemia patient. Ann Hematol. 88:495–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pescaramona E, Pignoloni P, Mauro FR,
Cerretti R, Anselmo AP, Mandelli F and Baroni CD:
Hodgkin/Reed-Sternberg cells and Hodgkin’s disease in patients with
B-cell chronic lymphocytic leukaemia: an immunohistological,
molecular and clinical study of four cases suggesting a
heterogeneous pathogenic background. Virchows Arch. 437:129–132.
2000.
|
|
15
|
Hamblin TJ, Davis Z, Gardiner A, Oscier DG
and Stevenson FK: Unmutated Ig V(H) genes are associated with a
more aggressive form of chronic lymphocytic leukemia. Blood.
94:1848–1854. 1999.PubMed/NCBI
|
|
16
|
Landgreen O, Pfeiffer RM, Stewart L,
Gridley G, Mellemkjaer L, Hemminki K, Goldin LR and Travis LB: Risk
of second malignant neoplasms among lymphoma patients with a family
history of cancer. Int J Cancer. 120:1099–1102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
World Health Organization. Monographs on
the evaluation of carcinogenic risks to humans – overall evaluation
of carcinogenety. IARC; Lyon: 1987
|
|
18
|
Maddocks-Christianson K, Slager SL, Zent
CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager
S, Jelinek DF, Kay NE and Shanafelt TD: Risk factors for
development of a second lymphoid malignancy in patients with
chronic lymphocytic leukaemia. Br J Haematol. 139:398–404. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheson BD, Vena DA, Barrett J and Freidlin
B: Second malignancies as a consequence of nucleoside analog
therapy for chronic lymphoid leukemias. J Clin Oncol. 17:2454–2460.
1999.PubMed/NCBI
|
|
20
|
Alebouyeh M, Moussavi F, Haddad-Deylami H
and Vossough P: Hodgkin lymphoma as second malignancy during
continuing chemotherapy for childhood acute lymphoblastic leukemia.
Klin Padiatr. 220:388–390. 2008. View Article : Google Scholar
|
|
21
|
Potocnik U, Ravnik-Glavac M and Glavac D:
Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4
mutations in colorectal tumors with high microsatellite
instability. Cell Mol Biol Lett. 7:92–95. 2002.PubMed/NCBI
|
|
22
|
Golapud S and Gupta S: Anti-P-glycoprotein
antibody-induced apoptosis of activated peripheral blood
lymphocytes: a possible role of P-glycoprotein in lymphocyte
survival. J Clin Immunol. 21:420–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wulf G, Kluding H, Ho AD, Doerner M,
Doehner H, Manegold C and Hunstein W: Multidrug resistance
phenotype in patients with chronic lymphocytic leukemia as detected
by immunofluorescence (FACS) and northen blot analysis. Leuk Res.
18:475–484. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marzolini C, Paulus E, Buclin T and Kim
RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances
and clinical relevance. Clin Pharmacol Ther. 75:13–33. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim DH, Park JY, Sohn SK, Lee NY, Baek JH,
Jeon SB, Kim JG, Suh JS, Do YR and Lee KB: Multidrug resistance-1
gene polymorphisms associated with treatment outcomes in the novo
acute myeloid leukemia. Int J Cancer. 118:2195–2201. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jamroziak K, Balcerczak E, Smolewski P,
Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kapłon A,
Mirowski M, Bates SE and Robak T: MDR1 (ABCB1) gene polymorphism
C3435T is associated with P-glycoprotein activity in B-cell chronic
lymphocytic leukemia. Pharmacol Rep. 58:720–728. 2006.PubMed/NCBI
|
|
27
|
Goreva OB, Grishanova AY, Mukhin OV,
Domnikova NP and Lyakhovich VV: Possible prediction of the
efficiency of chemotherapy in patients with lymphoproliferative
diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull
Exp Biol Med. 136:183–185. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Penna G, Allegra A, Alonci A, et al: MDR-1
polymorphisms (G2677T and C3435T) in B-chronic lymphocytic
leukemia: an impact on susceptibility and prognosis. Med Oncol. May
22–2010.(E-pub ahead of print).
|
|
29
|
Aydin S, Rossi D, Bergui L, D’Arena G,
Ferrero E, Bonello L, Omedé P, Novero D, Morabito F, Carbone A,
Gaidano G, Malavasi F and Deaglio S: CD38 gene polymorphism and
chronic lymphocytic leukemia: a role in transformation to Richter
syndrome? Blood. 111:5646–5653. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rossi D and Gaidano G: Richter syndrome:
molecular insights and clinical perspectives. Hematol Oncol.
27:1–10. 2009. View
Article : Google Scholar : PubMed/NCBI
|
